Active Monitoring of Adverse Drug Reactions Caused by Anti-tumor Targeted Drugs

doi:10.19803/j.1672-8629.2021.04.16

Abstract

Abstract: Objective To analyze the occurrence and characteristics of anti-tumor targeted drug adverse reactions (ADR), so as to provide reference for rational clinical use. Methods Through the results of active monitoring of China Hospital Pharmacovigilance System (CHPS), 120 inpatient medical records from A triple-A hospital’s May 5, 2016 to February 19, 2019 were extracted, and Excel software was used to analyze the ADR caused by anti-tumor targeted drugs. Results There were 120 cases of ADR induced by targeted drugs, the patients were mainly concentrated in 61~70 years (33.33%), and the ADR involved in the target drug was mainly in the digestive system (29.81%). the clinical manifestations were mainly gastrointestinal reactions. Conclusion The clinical use of targeted drugs should pay close attention to the adverse reactions of targeted drugs, in the course of treatment should do a good job of prevention and prognosis, pay close attention to the biochemical indicators before and after treatment, to ensure the safety of drug use.

Key words: targeted drugs, adverse drug reactions, active monitoring

CLC Number:

R969.3

CAI Meng, LI Min, SHEN Aizong. Active Monitoring of Adverse Drug Reactions Caused by Anti-tumor Targeted Drugs[J]. Chinese Journal of Pharmacovigilance, 2021, 18(4): 368-372.

References

[1] Germany Boehringer Ingelheim Pharma GmbH & Co. KG. Description of afatinib dimaleate capsule[EB/OL]. [2019-04-23].http://zy.yaozh.com/instruct/smshb20190415/199.pdf.
[2] Jiangsu Hengrui Medicine Co., Ltd. Description of apatinib mesylate tablets[EB/OL]. [2019-04-23].http://zy.yaozh.com/instruct/sms20180413/54.pdf.
[3] Roche Pharma(Switzerland)Ltd. Description of bevacizumab injection [EB/OL]. [2019-04-23]. http://zy.yaozh.com/instruct/20180711 sms/133.pdf.
[4] Roche Registration Ltd. Description of Tarceva(Erlotinib Hydrochloride Tablets) [EB/OL]. [2019-04-23]. http://zy.yaozh.com/instruct/ 20180606sms/a230.pdf.
[5] Astra Zeneca UK Limited. Description of Gefitinib Tablets[EB/OL]. [2019-04-23]. http://zy.yaozh.com/instruct/sms20181205hb/344.pdf.
[6] Roche Pharma (Schweiz)AG. Description of rituximab injection[EB/OL].[2019-04-23]. https://db.yaozh.com/instruct/103643.html.
[7] BSP Pharmaceuticals S.r.l. Description of Bortezomib for Injection[EB/OL]. [2019-04-23]. http://zy.yaozh.com/instruct/ypsms151012/34.pdf.
[8] Roche Pharma (Schweiz) Ltd. Description of Trastuzumab Injection[EB/OL]. [2019-04-23]. http://zy.yaozh.com/instruct/ 20180606sms/a468.pdf.
[9] Merck KGaA. Description of Cetuximab Solution for Infusion[EB/OL]. [2019-04-23]. http://zy.yaozh.com/instruct/sms20181205hb/2086.pdf.
[10] Takeda Pharma A/S. Description of Ixazomib Citrate Capsules [EB/OL]. [2019-04-23]. http://zy.yaozh.com/instruct/FDA/28.pdf.
[11] National Center for ADR Monitoring, State food and drug administration drug evaluation center. WHOART (WHO药品不良反应术语集)[M]. Beijing: China Medical Science and Technology Press, 2002:1-172.
[12] Wang D.Active surveillance of adverse drug reaction and Its development trend[J]. Chinese Journal of Pharmacovigilance(中国药物警戒) ,2015,12(10):600-602.
[13] National Center for ADR Monitoring. The National center held a ceremony to award the national ADR monitoring outpost [EB/OL]. (2017-12-14)[2018-06-20]. http://www.cdr-adr.org.cn/xwdt/ 201712/ t20171214 19834. html.
[14] Bass JM,Krens LL,Guchelaar HJ,et al.Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review[J]. Cancer Treatment Reviews,2012,38(5):505-514.
[15] He H, Zhu MT.Progress of ADR monitoring in China[J]. Journal of liaoning university of chinese medicine(辽宁中医药大学学报), 2018,20(6):142-145.
[16] Xiong R, Yin T, Duan CY, et al.Clinical observation of appatinib combined with systemic chemotherapy for liver metastasis of gastroenteropancreatic neuroendocrine neoplasm[J]. Chinese Pharmacy(中国药房),2019,30(6):821-824.
[17] Zhang M, Shi XD, Zhao P, et al.Analysis of clinicopathologic features, diagnosis and treatment of 405 cases with gastroenteropancreatic neuroendocrine neoplasm[J]. Chinese Journal of Digestion(中华消化杂志),2016,36(12):816-821.
[18] Wang FX, Shen QH, Fan GB, et al.Analysis of 190 cases of ADR reports in our hospital[J]. Chinese Pharmacy(中国药房), 2015,26(5):641-643.
[19] Huang L, Ma Z.The main adverse reactions and countermeasures of molecular targeted anti-tumor drugs[J]. Journal of Hubei University of Science and Technology (Medical Edition)[湖北科技学院学报(医学版)], 2018,32(6):545-549.
[20] Li D.Status quo of adverse reactions of 128 anti-tumor drugs[J]. China Medical Engineering(中国医学工程), 2019,27(3):102-104.
[21] Wang NN, Bai Y, Liu H, et al.Characteristics of adverse reactions of antineoplastic drugs in 787 cases and the prognosis analysis[J]. Anti-Tumor Pharmacy(肿瘤药学), 2019,9(1):143-148.
[22] Zhang Y.The manifestations and prevention and treatment of skin adverse reactions with EGFRI of targeted antitumor drugs[J]. Electronic Journal of Integrated Chinese and Western Medicine for Cardiovascular diseases(中西医结合心血管病电子杂志), 2018,6(27):198.
[23] Huang CL, Guo DH, Zhu M, et al.Analysis on 9819 cases of ADR/ADE associated with quinolones in military hospitals[J]. Drug application and monitoring in China(中国药物应用与监测), 2017, 14(5):293-296.
[24] Tian CH.Thinking to promote adverse drug reaction monito-ring work of medical institutions[J]. Chinese Journal of Pharma-covigilance(中国药物警戒) ,2016,13(5): 272-274.
[25] Ding PN,Lord SJ,Gebski V,et al.Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: A meta-analysis of clinical trials of gefitinib, and afatinib in advanced EGFR-mutated non-small gell lung cancer[J]. Journal of Thoracic Oncology: official publication of the International Association for the Study of Lung Cancer,2017,12(4): 633-643.
[26] Chen XQ, Jin YY, Tang G. Modern Pharmacology (新编药物学)[M]. Beijing: People's Medical Publishing House, 2011:17.